| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
6,495 |
5,065 |
$976K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
4,288 |
3,608 |
$354K |
| 80053 |
Comprehensive metabolic panel |
6,689 |
5,550 |
$332K |
| 36415 |
Collection of venous blood by venipuncture |
22,795 |
18,231 |
$246K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,958 |
1,826 |
$203K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
7,076 |
5,913 |
$162K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,248 |
1,174 |
$126K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
2,044 |
1,857 |
$82K |
| 87420 |
|
1,314 |
1,210 |
$73K |
| 87503 |
|
2,022 |
1,838 |
$42K |
| 84443 |
Thyroid stimulating hormone (TSH) |
932 |
824 |
$37K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
1,459 |
1,204 |
$32K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,674 |
1,592 |
$31K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
527 |
475 |
$30K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
644 |
542 |
$27K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
698 |
588 |
$26K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
118 |
93 |
$25K |
| 85048 |
|
2,741 |
1,931 |
$24K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
403 |
364 |
$22K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
488 |
422 |
$20K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
404 |
364 |
$18K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
740 |
651 |
$17K |
| 80061 |
Lipid panel |
400 |
350 |
$16K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,124 |
1,056 |
$16K |
| J2704 |
Injection, propofol, 10 mg |
388 |
315 |
$15K |
| 81001 |
|
797 |
679 |
$12K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
326 |
307 |
$10K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
189 |
176 |
$9K |
| 71046 |
Radiologic examination, chest; 2 views |
136 |
116 |
$9K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
176 |
140 |
$8K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
237 |
66 |
$7K |
| 85027 |
|
262 |
240 |
$6K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
97 |
86 |
$5K |
| 84145 |
|
125 |
96 |
$5K |
| 84484 |
|
110 |
96 |
$4K |
| 73630 |
|
51 |
38 |
$4K |
| A4217 |
Sterile water/saline, 500 ml |
103 |
60 |
$4K |
| 94760 |
|
143 |
115 |
$4K |
| 71045 |
Radiologic examination, chest; single view |
73 |
60 |
$4K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
148 |
119 |
$3K |
| 88142 |
|
66 |
63 |
$3K |
| 87480 |
|
52 |
51 |
$2K |
| 87660 |
|
52 |
51 |
$2K |
| 87510 |
|
52 |
51 |
$2K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
14 |
12 |
$2K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
13 |
13 |
$2K |
| 83605 |
|
69 |
51 |
$2K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
65 |
25 |
$2K |
| 0352U |
|
13 |
12 |
$2K |
| 82607 |
|
31 |
28 |
$1K |
| 87081 |
|
37 |
37 |
$1K |
| 83516 |
|
14 |
14 |
$1K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
20 |
12 |
$1K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
14 |
12 |
$1K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
54 |
12 |
$1K |
| 83735 |
|
50 |
43 |
$917.61 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
19 |
15 |
$831.67 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
15 |
12 |
$782.53 |
| 80306 |
|
12 |
12 |
$700.60 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
41 |
36 |
$625.21 |
| 81002 |
|
67 |
52 |
$436.11 |
| 81025 |
|
12 |
12 |
$291.69 |
| 85730 |
|
14 |
13 |
$232.10 |
| 81015 |
|
30 |
27 |
$198.99 |
| 85610 |
|
13 |
12 |
$158.28 |
| 82947 |
|
14 |
14 |
$43.00 |